Speaker Profile
M.D., Ph.D., Ensign Professor of Medicine, Deputy Director, and Chief of Medical Oncology and Hematology, Yale School of Medicine
Biography
Dr. Roy Herbst is a pioneer of personalized medicine and immunotherapy whose goal is to cure lung cancer. He has led Phase I development of multiple targeted agents for non-small cell lung cancer, including gefitinib, axitinib, atezolizumab, and anti-PD1PDL1 therapies. He has helped bring targeted therapy to early-stage disease as the PI of the adjuvant osimertinib study (ADAURA). He co-led MD Anderson's BATTLE-1 effort. He served as the national PI of the SWOG S0819 trial and held the role of founding PI for the NCI Lung Cancer Master Protocol (Lung-MAP, S1400) for a decade. He is a member of the National Cancer Policy Forum where he organizes National Academy of Medicine meetings focused on policy issues in personalized medicine and tobacco control. He is an elected member of the NCI Thoracic Malignancies Steering Committee and the chair of the American Association for Cancer Research Science Policy and Government Affairs Committee.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Jedd D. Wolchok, Weill Cornell Medicine
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Biomarker Decision Gates
• Chair: Levi Garraway, Roche
